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ABSTRACT 
Mutation / loss of alpha-thalassemia/mental retardation syndrome X-linked (ATRX) 
expression has been described in anaplastic gliomas. The present study explored the 
role of ATRX status in the molecular classification of anaplastic gliomas and its 
impact on survival in the biomarker cohort of the NOA-04 anaplastic glioma trial. 
Patients (n = 133) of the NOA-04 trial were analyzed for ATRX expression using 
immunohistochemistry. ATRX status was correlated with age, histology, isocitrate 
dehydrogenase (IDH), 1p/19q, alternative lengthening of telomeres (ALT) and O6-
methylguanine-DNA methyltransferase (MGMT) status, and the trial efficacy 
endpoints.  
Loss of ATRX expression was detected in 45% of anaplastic astrocytomas (AA), 27% 
of anaplastic oligoastrocytomas (AOA) and 10% of anaplastic oligodendrogliomas 
(AO). It was mostly restricted to IDH mutant tumors and almost mutually exclusive 
with 1p/19q co-deletion. The ALT phenotype was significantly correlated with ATRX 
loss. ATRX and 1p/19q status were used to re-classify AOA: AOA harboring ATRX 
loss shared a similar clinical course with AA whereas AOA carrying 1p/19q co-
deletion shared a similar course with AO. Accordingly, in a Cox regression model 
including ATRX and 1p/19q status, histology was no longer significantly associated 
with time to treatment failure. Survival analysis showed a marked separation of IDH 
mutant astrocytic tumors into two groups based on ATRX status: Tumors with ATRX 
loss had a significantly better prognosis (median time to treatment failure 55.6 vs. 
31.8 months, p = 0.0168, log rank test). 
ATRX status helps to better define the clinically and morphologically mixed group of 
AOA, since ATRX loss is a hallmark of astrocytic tumors. Furthermore, ATRX loss 
defines a subgroup of astrocytic tumors with a favorable prognosis. 
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INTRODUCTION 
The WHO classification, based solely on morphological criteria [16], may be 
increasingly supplemented with defined molecular aberrations [5, 19, 22, 24]. These 
might help to resolve the discrepancy between classification and clinical outcome. A 
prototypical example for this discrepancy are anaplastic oligoastrocytomas, which are 
histologically and molecularly mixed gliomas, displaying both astrocytic and 
oligodendroglial features [17, 18]. As a result, the diagnosis of oligoastrocytomas is 
subject to high interobserver variation [12]. 
The prognostic or predictive impact of mutations of the isocitrate dehydrogenase 1 
and 2 genes (IDH1/2), hypermethylation of the O6-methylguanine-DNA 
methyltransferase (MGMT) promoter and co-deletion of 1p and 19q have been 
extensively characterized [26]. Recently, mutations and (consequently) loss of 
expression of alpha-thalassemia/mental retardation syndrome X-linked (ATRX) have 
been reported in one third of pediatric glioblastomas [20] and 7% of adult 
glioblastomas [7]. Virtually all mutations are inactivating and lead to a loss of protein 
expression [7, 15]. Mechanistically, loss of ATRX and death-domain associated 
protein (DAXX) are important factors for a telomere maintenance mechanism not 
involving telomerases (alternative lengthening of telomeres (ALT)). A number of 
studies have analyzed the frequency of ATRX mutation / loss of expression and its 
correlation with molecular markers in glioma: In pediatric diffuse intrinsic pons 
gliomas, ATRX mutation occurred in 2 of 22 cases [10]. High-throughput 
resequencing revealed ATRX mutations to be present in 12 of 32 (37.5%) grade II 
and III gliomas examined. In this cohort, ~ 70% of IDH mutant, 1p/19q intact tumors 
carried ATRX mutations [9]. ATRX loss assessed by immunohistochemistry has been 
reported as 27% in grade II and 41% in grade III astrocytomas in adults, compared to 
a mutation rate of 33% and 46%, respectively [15]. Another recent study described a 
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significantly higher mutation rate of 73% in 44 anaplastic astrocytoma [8]. Notably, 
these studies showed that loss of ATRX expression is more prevalent in astrocytic 
than in mixed glial tumors and rare in pure oligodendrogliomas. Loss of ATRX 
expression is highly associated with IDH mutation and almost mutually exclusive with 
1p/19q co-deletion, the hallmark of oligodendroglial tumors. 
The prognostic value of ATRX status in different tumor entities has remained 
controversial: In pancreatic neuroendocrine tumors, altered ATRX expression has 
been associated with a more aggressive phenotype [25]. In childhood acute myeloid 
leukemia carrying FLT3 mutations, higher ATRX expression was associated with a 
superior outcome [13]. In gliomas, ATRX mutation has been associated with a better 
prognosis in a retrospective cohort of grade II, III and IV tumors [8].  
The Neurooncology Working Group of the German Cancer Society (NOA)-04 trial 
explored the optimal sequence of radiotherapy and alkylating chemotherapy in 
patients with newly diagnosed, centrally confirmed anaplastic gliomas. NOA-04 
revealed initial radiotherapy or chemotherapy to be comparable and IDH mutations 
as a novel positive prognostic factor in anaplastic gliomas [27]. In the NOA-04 trial 
cohort, we sought to determine the prognostic value of ATRX status as well as its 
implications for molecular classification of anaplastic gliomas, especially mixed 
oligoastrocytomas.  
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METHODS 
Patients, evaluations and ethics 
The NOA-04 trial (NCT00717210) compared the efficacy of safety of initial 
radiotherapy, followed by chemotherapy (temozolomide or procarbazine, lomustine 
and vincristine) at progression or occurrence of unacceptable toxicity with the inverse 
sequence in patients with newly diagnosed anaplastic gliomas. In this trial, both 
sequences achieved similar results. Median follow-up time was 54 months [27]. All 
patients consented to exploratory molecular analyses performed with study data and 
materials. The original phase III trial was approved by the Ethics Committee (EC) at 
the University of Tuebingen, Germany, and subsequently all local EC. NOA-04 
enrolled patients after written informed consent including future molecular analyses at 
39 German sites. 
 
Molecular analyses 
IDH1/2 mutations, MGMT promoter methylation and 1p/19q co-deletion were 
determined as described in the initial trial report [27]. 
 
ATRX immunohistochemistry 
ATRX immunohistochemistry polyclonal rabbit antibody, dilution 1:400, product code 
HPA001906, Sigma-Aldrich, St. Louis, MO, USA) was performed using an automated 
immunostainer (Benchmark Ultra, Ventana, Tucson, AZ, USA) and standard 
protocols including pretreatment using Cell Conditioning 1 buffer (Ventana) for 52 min 
and standard Ventana signal amplification. Evaluation was performed by two 
observers (BW and DC) simultaneously on a multi-headed microscope and scoring 
was done in consensus. Only nuclear staining was considered for evaluation. Cases 
with more than 10% positive tumor cells were scored positive. Endothelial cells, 
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cortical neurons and infiltrating inflammatory cells were generally positive and served 
as internal positive controls. Cases with negative tumors cells in which vessel cells 
and neurons were not stained were not evaluated and not considered for further 
statistical evaluation (n = 13 cases). In cases with inhomogenous immunoreaction, 
areas with highest staining were scored. 
 
ALT fluorescence in situ hybridization  
Telomere specific fluorescence in situ hybridization (FISH) was done using a 
standard formalin-fixed paraffin-embedded FISH protocol [20], using a FITC peptide 
nucleic acid telomere probe from Dako. Large, ultra-bright telomere DNA 
aggregates/clouds are unique to ALT-positive cells and are significantly larger and 
brighter than the FISH signals emitted from individual telomeres in the same cell 
population and control CNS tissue samples. 
 
Statistics 
The co-occurrence of ATRX loss and reference histology, ALT, IDH1/2 and p53 
mutations, MGMT promoter methylation and 1p/19q co-deletion was assessed using 
Fisher’s exact test. One-way ANOVA was employed to compare mean age between 
different groups followed by a pairwise t test comparison with Bonferroni correction. 
Wilcoxon rank sum test was used for comparing ATRX expression data between 
ATRX mutated and wild type groups. Univariate survival analysis was performed 
using the Kaplan-Meier estimator and log rank test. Multivariate analysis used a Cox 
proportional hazards model. p < 0.05 was considered statistically significant. All tests 
were two-sided. Analyses were carried out using Stata IC version 12.1 (StataCorp 
LP, TX, USA). 
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RESULTS 
ATRX loss occurs predominantly in astrocytic tumors with IDH mutation and is 
almost mutually exclusive with 1p/19q co-deletion 
The present NOA-04 biomarker cohort comprised 133 of the 274 patients of the 
NOA-04 intention-to-treat (ITT) population for which unstained paraffin slides were 
available. Baseline characteristics of the biomarker cohort and the ITT population 
were similar (Table 1). 
ATRX immunohistochemistry was positive in 89 of 133 cases with a strong nuclear 
immunreaction in most cases (Fig. 1a). Loss of ATRX was evident in 44 of 133 cases 
with the bulk of tumor cells negative for ATRX whereas endothelia and infiltrating 
inflammatory cells as well as residual neurons retained ATRX expression (Fig. 1b). 
In 13 cases no immunoreaction was observed in the entire tissue, these cases were 
not scored and consequently not considered for statistical evaluation. As reported 
earlier, the frequency of ATRX loss was higher in anaplastic astrocytomas (AA, 29 / 
65, 45%) than in anaplastic oligoastrocytomas (AOA, 13 / 48, 27%) and low in 
anaplastic oligodendrogliomas (AO, 2 / 20, 10%, p = 0.009, Fisher’s exact test). 
ATRX loss occurred almost exclusively in tumors harboring IDH mutations (42 / 98 
IDH mutated tumors, 43%). Only two patients who were IDH wild type had ATRX 
loss. Patients with ATRX loss and IDH mutation were younger (mean age 35.7 years, 
n = 42) than patients with ATRX expression and IDH mutation (mean age 46.8 years, 
n = 56, p < 0.0001, one-way ANOVA) or IDH wild type patients with ATRX expression 
(mean age 54.1 years, n = 30, p < 0.0001, one-way ANOVA). 
ATRX loss and 1p/19q co-deletion were almost mutually exclusive. Only two AA and 
one AOA showed both ATRX loss and 1p/19q co-deletion. The two AO with ATRX 
loss did not have a 1p/19q co-deletion. No association between MGMT promoter 
methylation and ATRX loss was observed (p = 0.445, Fisher’s exact test, Table 2). 
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We assessed the association of ATRX status and the ALT phenotype by FISH. In a 
set of 29 randomly chosen samples, we observed ALT in 11 of 15 samples which 
harbored ATRX loss, but only in 3 of 14 samples with retained ATRX expression (p = 
0.009, Fisher’s exact test). 
 
ATRX loss is a favorable prognostic marker 
In a univariate Cox regression model, reference histology was significantly 
associated with time to treatment failure (TTF), the primary endpoint of the NOA-04 
trial (Table 3a). Upon incorporation of both ATRX and 1p/19q status into the model 
(Table 3b), the prognostic value of reference histology was no longer significant, 
while both ATRX loss and 1p/19q co-deletion were associated with TTF. Based on 
this, we grouped mixed AOA without 1p/19q co-deletion but with ATRX loss and AA 
(both with and without ATRX loss, but without 1p/19q co-deletion) into “molecular 
astrocytomas”. Likewise, we combined AOA harboring 1p/19q co-deletion and AO 
(both with and without 1p/19q co-deletion, but without ATRX loss) into “molecular 
oligodendrogliomas”. Tumors with IDH wild type tumors behaved like “molecular 
glioblastomas” in analogy to [6] (Fig. 2). Kaplan-Meier plots for TTF based on 
reference histology (Fig. 3a) and “molecular histology” (Fig. 3b-d) demonstrate the 
highly similar course for AA and AOA (Fig. 3c) as well as AO and AOA (Fig. 3d), 
respectively, when grouped by ATRX expression and 1p/19q co-deletion status. 
Survival analysis of the “molecular astrocytomas” demonstrated a marked separation 
of the clinical course of IDH mutant tumors based on ATRX status. Patients with 
tumors with ATRX loss had a longer time to treatment failure (median TTF 55.6 
months [95% CI 45.1 months – to not reached], n = 40) than patients with IDH mutant 
tumors with ATRX expression (median TTF 31.8 months [95% CI 2.8 months – to not 
reached], n = 9, p = 0.0168, log rank test; Fig. 3e). For PFS, similar results were 
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obtained (median PFS 37.1 vs. 18.1 months, p = 0.038, log rank test; 
Supplementary Fig. 1), while for an analysis of OS, the number of events at a 
median follow-up of 54 months was too small. 
To determine predictive properties of the molecular subgrouping, we assessed PFS 
and TTF for the two treatment arms in “molecular astrocytomas”, “molecular 
oligodendrogliomas” and “molecular glioblastomas” (Supplementary Fig. 2): We 
observed a trend towards a longer PFS in “molecular astrocytomas” who initially 
received radiotherapy compared to chemotherapy (median PFS 50.6 vs. 25.1 
months, p = 0.0944; Supplementary Fig. 2a). For TTF, this difference between the 
groups narrowed (median TTF 55.6 vs. 45.1 months, p = 0.2784, log rank test; 
Supplementary Fig. 2b), suggesting that patients who initially were treated with 
chemotherapy still benefited from radiotherapy at recurrence. Treatment efficacy was 
similar for radio- and chemotherapy in the other two molecular groups 
(Supplementary Figure 2c-f). 
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DISCUSSION 
Molecular classification of malignant glioma has been receiving increasing attention 
lately. ATRX mutation and loss of expression, which has just recently been 
discovered in gliomas [7], might further refine this classification. Using 
immunohistochemistry to assess ATRX expression in a subset of the NOA-04 trial 
patient population, we detected ATRX loss in approximately 40% of AA and 25% of 
mixed AOA. In contrast, ATRX loss was rare in AO. ATRX loss has been reported 
before to be scarce in oligodendrogliomas [9, 15] and mutually exclusive with 1p/19q 
co-deletion in non-astrocytic tumors [8]. 
Given the separate clinical course [6] and possibly cell of origin [14] of anaplastic 
tumors which are IDH wild type, these tumors should be considered a distinct group 
and seem most closely related to primary glioblastomas. From the distribution of 
ATRX status and a similar clinical course of IDH mutant AA and AOA (Fig. 3c), we 
suggest grouping AA and mixed AOA without 1p/19q co-deletion but with ATRX loss 
as “molecular anaplastic astrocytomas”. 1p/19q co-deletion on the other hand is 
considered a hallmark of oligodendroglial tumors [21] and was suggested a predictive 
biomarker for radiochemotherapy with procarbacin, CCNU and vincristin in two 
independent trials of anaplastic oligodendroglial tumors [2, 4]. Based on the above, 
AOA which harbor 1p/19q co-deletion and AO can be classified as “molecular 
anaplastic oligodendroglioma” (Fig. 4). Kaplan-Meier curved indeed demonstrated a 
very similar course for AA and AOA as well as AO and AOA, when grouped as 
described above (Fig. 3c-d). Using this approach, only 9 of 133 tumors (6%) could 
not be classified. Of these, two samples carried both 1p/19q co-deletion and ATRX 
loss and two had a missing IDH status. 
Prior studies have reported a discrepancy in the frequency of ATRX deficiency: While 
two studies reported a ~ 70% prevalence of ATRX deficiency in IDH mutant, 1p/19q 
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intact tumors [8, 9], another study reported a < 50% prevalence [15]. In the NOA-04 
cohort, ATRX loss occurred in 65% of IDH mutant, 1p/19q intact cases (28 of 43). As 
expected, ATRX loss was rare both in 1p/19q co-deleted (3 of 43, 7%) and IDH wild 
type tumors (2 of 32, 6%). The high prevalence of ATRX loss in this tumor subset, as 
reported by others, argues for ATRX deficiency as a class-defining feature. 
NOA-04 showed a highly similar clinical course for AO and AOA [27], which others 
have questioned. In the EORTC 26951 trial, AOA had a worse outcome compared to 
pure AO [3]. A retrospective panel review of 150 patients from the EORTC 26951 
trial, which did not impose such a restrictive central histology, confirmed on 
consensus only 8% of the local AOA diagnoses [12]. In NOA-04 on the other hand, a 
restrictive central histological AOA classification, which required unambiguous 
oligodendroglial differentiation features probably enriched the group of AOA for AO: 
Following the above concept of molecularly assisted subgrouping, of the 48 AOA of 
the NOA-04 trial, 12 AOA would be grouped with the AA, while 23 tumors would be 
considered as AO. 8 AOA were IDH wild type, while 5 AOA could not be re-assigned 
(for 2 of these, 1p/19q status is missing; Fig. 2). Due to the retrospective nature of 
this study, no DNA of sufficient quality was available for these tumors to sequence 
ATRX and complement 1p/19q testing.  
A better prognosis for patients with ATRX mutations has been suggested in a 
retrospective cohort by Jiao et al. [8]: These authors proposed a classification of 
anaplastic tumors - irrespective of histology - based on ATRX, CIC, FUBP1 and IDH 
status and postulated a significantly longer overall survival for patients with either 
ATRX or CIC & FUBP1 mutations (who all carried IDH mutations as well) compared 
to patients with IDH mutant tumors which were wild type for ATRX, CIC and FUBP1. 
We grouped the 133 NOA-04 samples accordingly, resulting in 40 patients with 
ATRX loss, 40 patients with 1p/19q co-deletion, 17 patients with IDH mutation only 
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and 31 patients who were IDH wild type. Five patients could not be classified using 
this approach (including three patients with both ATRX loss and 1p/19q co-deletion). 
While median TTF was longer for 1p/19q co-deleted tumors (median TTF not 
reached), it was similar for tumors with ATRX loss (median TTF 55.6 months) and 
IDH mutation only (58.3 months, p = 0.3761, log rank test, Supplementary Fig. 3). 
However, using our approach which incorporates histology (Fig. 4), ATRX status 
separated “molecular astrocytomas” into two groups, with a significantly better 
prognosis for patients with tumors with ATRX loss (Fig. 3e). Given the superior 
clinical course of oligodendroglial tumors, it seems to be important to evaluate the 
prognostic value of ATRX status only in astrocytic tumors as we did here. To this 
extent, ATRX status is important as it both helps to re-classify mixed oligoastrocytic 
tumors and defines a subgroup of astrocytic tumors with a superior clinical course. 
ATRX plays a role in regulating chromatin remodeling [1] and is tightly associated 
with IDH mutations, which are linked with a distinct epigenetic signature [23], the 
glioma CpG island methylator phenotype (G-CIMP). Thus, epigenetic differences 
between ATRX expressers vs. non-expressers may underlie the distinct clinical 
course in astrocytic tumors. 
In pediatric glioblastomas, ATRX mutations have been identified in tumors with 
H3F3A mutations [20]. However, given that almost all tumors in this NOA-04 
biomarker cohort which had ATRX loss were IDH mutated (Table 2), and H3F3A and 
IDH mutations are mutually exclusive [20, 22], we did not test for H3F3A mutations. 
We confirmed the association between ATRX loss and the ALT phenotype. Another 
mechanism for tumor cell telomere maintenance involves the telomerase reverse 
transcriptase (TERT). Point mutations in the promoter of the TERT gene increase 
telomerase expression and have been shown to occur frequently in gliomas. In AO 
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and AOA, TERT mutations exclusively occurred in 1p/19 co-deleted tumors. In all 
anaplastic tumors TERT mutations and ATRX losses were mutually exclusive [11]. 
This study is limited by the rather small sample size and the lack of DNA of sufficient 
quality to verify ATRX mutations. However, the use of immunohistochemistry allows 
for a broad application of ATRX testing in practice. Furthermore, a good concordance 
between ATRX mutations and loss of ATRX expression (as assessed through IHC) 
has been reported [7, 15].  
ATRX in conjunction with 1p/19q status may help to unequivocally classify mixed 
gliomas, whose diagnoses are subject to relevant inter-observer variation, as either 
astrocytic or oligodendroglial. More important than this potential facilitation of the 
diagnosis is the prognostic value of the molecular classification itself (Fig. 4): In this 
prospective cohort, patients with astrocytic tumors harboring ATRX loss have a 
significantly better prognosis than IDH mutant patients with astrocytic tumors who 
express ATRX. 
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FIGURE LEGENDS 
Fig. 1 IHC staining for ATRX. (a-b) IHC staining of one tumor sample with retained 
ATRX expression (a), and another tumor sample with ATRX loss (b). Note the ATRX 
positive endothelial cells in (b) 
Fig. 2 Overview of reference histology, molecular aberrations and molecular 
diagnosis in NOA-04 patients (n = 133). Every column represents a patient. 
“Molecular diagnosis” is defined as astrocytoma (IDH mutant AOA with ATRX loss 
and IDH mutant AA with or without ATRX loss, but without 1p/19q co-deletion; n = 
49), oligodendroglioma (IDH mutant AOA with 1p/19q co-deletion and IDH mutant AO 
with or without 1p/19q co-deletion, but without ATRX loss; n = 43), glioblastoma (IDH 
wild type; n = 32) or non-classifiable (n = 9) 
Fig. 3 Influence of ATRX on classification and survival. (a) Time to treatment 
failure, separated by reference histology. (b-d) TTF by molecular diagnosis (b) and 
for “molecular astrocytomas” (c) and “molecular oligodendrogliomas” (d), separated 
by reference histology. (e) Time to treatment failure “molecular astrocytoma” grouped 
by ATRX status 
Fig. 4 Proposed molecular classification of anaplastic gliomas based on 
histology and molecular markers. Length of the green bars represents the 
proportion of IDH wild type tumors, whereas the yellow and blue bars represent IDH 
mutant tumors. Mixed anaplastic oligoastrocytoma harboring IDH mutation are 
molecularly classified as either oligodendrogliomas (carrying 1p/19q co-deletion) or 
astrocytomas (carrying ATRX loss)  
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Table 1. Baseline patient characteristics 
 NOA-04 Biomarker Cohort NOA-04 Trial Cohort 
 RT 
(n = 67) 
PCV / TMZ 
(n = 66) 
RT 
(n = 139) 
PCV / TMZ
(n = 135) 
Median age 
(range), years 
42 
(23 – 74) 
42 
(20 – 71) 
44 
(23 – 74) 
42 
(20 – 77) 
Astrocytoma, n 
Oligoastrocytoma, n 
Oligodendroglioma, n 
33 (49%) 
21 (32%) 
13 (19%) 
32 (48%) 
27 (41%) 
7 (11%) 
70 (50%) 
47 (34%) 
22 (16%) 
74 (55%) 
44 (32%) 
17 (13%) 
Resection, n 
Total 
Subtotal 
Biopsy 
 
29 (43.5%) 
30 (44.5%) 
8 (12%) 
 
26 (40%) 
33 (49%) 
7 (11%) 
 
53 (38%) 
61 (44%) 
25 (18%) 
 
47 (35%) 
57 (42%) 
31 (23%) 
1p/19q co-deletion, n 
Yes 
No 
Information missing 
 
23 (40%) 
34 (60%) 
10 
 
20 (38%) 
34 (62%) 
12 
 
41 (43%) 
54 (57%) 
44 
 
33 (38%) 
53 (62%) 
49 
MGMT promoter, n 
Methylated 
Unmethylated 
Information missing 
 
33 (52%) 
30 (48%) 
4 
 
41 (64%) 
23 (36%) 
2 
 
59 (57%) 
44 (43%) 
36 
 
64 (64%) 
35 (36%) 
36 
IDH mutation, n 
Yes 
No 
Information missing 
 
50 (76%) 
16 (24%) 
1 
 
48 (75%) 
16 (25%) 
2 
 
65 (66%) 
33 (34%) 
41 
 
68 (70%) 
29 (30%) 
38 
RT, radiotherapy; PCV, procarbazine, CCNU & vincristine; TMZ, temozolomide 
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Table 2. Molecular characteristics of anaplastic gliomas by ATRX status  
 ATRX expressed (n = 89) ATRX lost (n = 44) 
Astrocytoma, n 
Oligoastrocytoma, n 
Oligodendroglioma, n 
36 (40%) 
35 (40%) 
18 (20%) 
29 (65%) 
13 (30%) 
2 (5%) 
1p/19q co-deletion, n 
Yes 
No 
Information missing 
 
40 (50.5%) 
39 (49.5%) 
10 
 
3 (9%) 
29 (91%) 
12 
MGMT promoter, n 
Methylated 
Unmethylated 
Information missing 
 
52 (61%) 
33 (39%) 
4 
 
22 (57%) 
20 (43%) 
2 
IDH mutation, n 
Yes 
No 
Information missing 
 
56 (65%) 
30 (35%) 
3 
 
42 (95.5%) 
2 (4.5%) 
0 
ALT phenotype, n 
Yes 
No 
Information missing 
 
3 (21%) 
11 (79%) 
75 
 
11 (75%) 
4 (25%) 
29 
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Table 3. Uni- and multivariate Cox regression models for TTF 
a) Univariate Cox model of reference histology 
Variable Hazard Ratio 95% CI p 
AO vs. AA 0.38 0.17 – 0.85 0.019 
AOA vs. AA 0.33 0.18 – 0.59 < 0.001 
 
b) Multivariate Cox model of reference histology, ATRX and 1p/19q status 
Variable Hazard Ratio 95% CI p 
AO vs. AA 0.55 0.22 – 1.34 0.19 
AOA vs. AA 0.54 0.23 – 1.24 0.147 
ATRX loss vs. expression 0.26 0.12 – 0.55 < 0.001 
1p/19q co-deletion, yes vs. no 0.17 0.07 – 0.42 < 0.001 
AO, anaplastic oligodendroglioma; AOA, anaplastic oligoastrocytoma; AA, anaplastic 
astrocytoma 
 
 


